Shingrix: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing Local Product Insert

Concise Prescribing Info

Contents

Herpes zoster vaccine [varicella zoster virus glycoprotein E antigen (non-live, recombinant, AS01_B adjuvanted)]

Indications/Uses

Prevention of herpes zoster (HZ) & HZ-related complications eg, post-herpetic neuralgia in adults ≥50 yr & ≥18 yr at increased risk of HZ.

Click to view Shingrix detailed prescribing information

Dosage/Direction for Use

IM Inj in deltoid muscle. Primary vaccination schedule of 2 doses (0.5 mL each). Initial dose followed by 2nd dose 2-6 mth later. Immunodeficient, immunosuppressed individual or those likely to become immunosuppressed due to known disease or therapy, & whom shorter vaccination schedule is beneficial 2nd dose can be given 1-2 mth after initial dose.

Click to view Shingrix detailed prescribing information

Overdosage

View Shingrix overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Shingrix detailed prescribing information

Special Precautions

Not indicated for prevention of primary varicella infection. Not to be administered as intravascular, intradermal or SC. Postpone vaccination in subjects suffering from acute severe febrile illness. Syncope. Patients w/ thrombocytopenia or any coagulation disorder. Review medical history & perform clinical exam prior to immunisation. Pregnancy & lactation. Increased risk of Guillain-Barré syndrome during 42 days following vaccination in elderly ≥65 yr.

Click to view Shingrix detailed prescribing information

Use In Pregnancy & Lactation

Click to view Shingrix detailed prescribing information

Adverse Reactions

Headache; GI symptoms including nausea, vomiting, diarrhoea &/or abdominal pain; myalgia; inj site reactions (eg, pain, redness, swelling), fatigue, chills, fever. Inj site pruritus, malaise.

Click to view Shingrix detailed prescribing information

Drug Interactions

More frequent adverse reactions eg, fever & shivering w/ 23-valent pneumococcal polysaccharide vaccine (PPV23). Administer at different inj site if to be given at the same time as another injectable vaccine.

Click to view Shingrix detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Shingrix detailed prescribing information

Storage

View Shingrix storage conditions for details to ensure optimal shelf-life.

Description

View Shingrix description for details of the chemical structure and excipients (inactive components).

Action

View Shingrix mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BK - Varicella zoster vaccines ; Used for active immunizations.

Thai FDA Category

Presentation/Packing

Form

Shingrix powd & susp for inj 50 mcg (0.5 mL)/dose

Packing/Price

0.5 mL x 1's

Shingrix

recombinant varicella-zoster virus glycoprotein e antigen vaccine

Manufacturer:

GlaxoSmithKline Biologicals

Distributor:

Zuellig Pharma

Marketer:

GlaxoSmithKline